# Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

> **NCT00520533** · PHASE1 · TERMINATED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 8 (actual)

## Conditions studied

- Renal Cell Carcinoma (RCC)

## Interventions

- **BIOLOGICAL:** Chimeric monoclonal antibody cG250
- **DRUG:** Sunitinib malate

## Key facts

- **NCT ID:** NCT00520533
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2011-07
- **Final completion:** 2012-09
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Closed prematurely due to toxicity
- **Last updated:** 2022-10-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520533, "Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00520533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*